news
-
DOSIsoft Announces New FDA 510(k) Clearance for PLANET® Onco Dose
- March 25, 2025
DOSIsoft, SA is proud to announce its latest product release, PLANET® Onco Dose version 3.2 received FDA 510(k) Clearance on March 14, 2025 from the US Food and Drug Administration, following its EU MDR CE Mark certification. The novel PLANET® platform is designed to incorporate a multi-radionuclide approach, implement multi-workflow solutions, and support multi-therapy applications for both SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) while ensuring compliance with U.S. standards.
-
PLANET® Onco Dose Receives EU MDR CE Mark certification
- March 4, 2025
DOSIsoft is proud to announce that its latest product release, PLANET® Onco Dose version 3.2 – multi-radionuclide, personalized, voxel-based dosimetry platform for both SIRT and MRT – received Medical Device Regulation (MDR) CE Mark on February 17, 2025, under the new (EU) Regulation 2017/745.
-
JFMN 2025
- February 14, 2025
11th Annual Congress of JFMN (Journées Francophones de Médecine Nucléaire)
March 20-22, 2025
Montrouge, France
Booth #6a -
ALFIM Congress 2025
- February 13, 2025
10th Latin American Congress of Medical Physics (ALFIM)
March 9-12, 2025
La Antigua, Guatemala
Patient QA showcase on Elekta booth -
Happy New Year 2025
- December 26, 2024
-
[Article] Dosimetric Evaluation of 177Lu Peptide Receptor Radionuclide Therapy Using GATE and Planet Dose
- December 6, 2024
Ioanna Stamouli, Thomas Nanos, Konstantinos Chatzipapas, Panagiotis Papadimitroulas, Lydia-Aggeliki Zoglopitou, et al.
Appl. Sci. 2023, 13, 9836. | https://doi.org/10.3390/app13179836 -
ALATRO Congress 2024
- November 4, 2024
9th Asociación Ibero-Latinoamericana de Terapia Radiante Oncológica (ALATRO) Meeting
November 6-9, 2024
Río de Janeiro, Brasil
Patient QA showcase on Elekta booth -
DOSIsoft Contributing Partner of the European Thera4Care project – Theranostics Ecosystem For Personalized Care
- October 11, 2024
DOSIsoft is proud to be part of the EU-funded Thera4care Project – a public-private initiative aiming to revolutionize precision oncology and establish Europe as a global leader in Theranostics. Contributing with its own R&D and granted 1,6 million€ of EU funding, DOSIsoft will focus its efforts on the further development of dosimetry software, sharing the vision that personalized dosimetry becomes a standard clinical practice.
-
DOSIsoft & AP-HP: A Scientific partnership on « QUANTHYR » – 1st Software dedicated to Personalized Diagnosis and Dosimetry Treatment of Hyperthyroidism with 131Iodine
- October 1, 2024
RESEARCH & INNOVATION IN NUCLEAR MEDICINE: To improve cancer patient safety and treatment quality, DOSIsoft announces that it has signed a development and commercialization agreement (license) with the Assistance Publique – Hôpitaux de Paris (AP-HP) for a Radioiodine theranostic solution applied to benign thyroid diseases named “QUANTHYR”.
-
EANM Annual Congress 2024
- September 6, 2024
The 37th Annual Congress of the European Association of Nuclear Medicine
October 19-23, 2024
Hamburg, Germany
Booth #S4